Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Severe pertussis infections in pediatric intensive care units: a multicenter study.
Eur J Pediatr
January 2025
Department of Biostatistics and Medical Informatics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
Unlabelled: This study aims to evaluate the clinical course of critical pertussis illness to the pediatric intensive care unit in Istanbul. The study was conducted as a multicenter, retrospective study between January 1, 2023, and December 31, 2023. Cases with positive polymerase chain reaction testing for Bordetella pertussis of nasopharyngeal swab samples within the first 24 h of pediatric intensive care unit admission were recorded.
View Article and Find Full Text PDFAllergic Reactivity and Memory Occur Independently of Sequential Switching Through IgG1.
Allergy
January 2025
Schroeder Allergy and Immunology Research Institute, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Allergic reactions to foods are primarily driven by allergen-binding immunoglobulin (Ig)E antibodies. IgE-expressing cells can be generated through direct switching from IgM to IgE or a sequential class switching pathway where activated B cells first switch to an intermediary isotype, most frequently IgG1, and then to IgE. It has been proposed that sequential class switch recombination is involved in augmenting the severity of allergic reactions, generating high affinity IgE, differentiation of IgE plasma cells, and in holding the memory of IgE responses.
View Article and Find Full Text PDFPromoting Physical Activity in People With Parkinson's Disease Through a Smartphone App: A Pilot Study.
J Neurol Phys Ther
January 2025
Center of Expertise for Parkinson & Movement Disorders, Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands (S.S., N.M.V., S.K.L.D., B.R.B.); Harvard Medical School, Boston, Massachusetts (A.A., M.A.S., E.A.M.); Departments of Epidemiology and Nutrition, T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts (A.A.); Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts (M.A.S., E.A.M.); Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, Massachusetts (M.A.S.); and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts (E.A.M.).
Background And Purpose: Physical activity has beneficial symptomatic effects for people with Parkinson's disease (PD), but increasing-and sustaining-a physically active lifestyle remains challenging. We investigated the feasibility (ability to increase step counts) and usability of a behavioral intervention using a motivational smartphone application to remotely increase physical activity in PD.
Methods: We performed a 4-week, double-blind pilot trial.
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Eur J Neurol
January 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Objective: To investigate the impact of transition interval length when switching from natalizumab (NTZ) to anti-CD20 monoclonal antibodies (antiCD20) on recurrent disease activity and safety in relapsing multiple sclerosis (RMS).
Methods: Aggregating data from 8 MS centres in Austria, Switzerland, and Germany, we included RMS patients who (i) continuously received NTZ for ≥3 months, (ii) were switched to antiCD20, and (iii) had ≥12 months follow-up after switch. The primary endpoint was occurrence of relapse after switch, secondary endpoints included severe infections (CTCAE grade ≥3).
Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.
BioDrugs
December 2024
Department of Allergy and Clinical Immunology, St James' University Hospital, Leeds, UK.
B-cell depleting therapy (BCDT) has revolutionised the treatment of B-cell malignancies and autoimmune diseases by targeting specific B-cell surface antigens, receptors, ligands, and signalling pathways. This narrative review explores the mechanisms, applications, and complications of BCDT, focusing on the therapeutic advancements since the introduction of rituximab in 1997. Various monoclonal antibodies and kinase inhibitors are examined for their roles in depleting B cells through antibody-dependent and independent mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!